Dr. Christopher Gondi is a Research Assistant Professor in the Department of Internal Medicine at the University of Illinois College of Medicine. He has a broad background in cancer research, specifically focusing on therapy resistance. Dr. Gondi’s previous research work related to gene therapy in brain tumors had resulted in a patent and is currently in the pre-clinical phase.
His research on Neuroblastoma has demonstrated the involvement of the microRNA (miR-410) machinery in suppression of angiogenesis and that the development of therapy resistance involves nMYC copy number changes. He continues to work on therapy resistance currently focused on pancreatic cancer.
Specifically, his focus is to develop strategies to sensitize pancreatic cancer cells to chemotherapy making them responsive at lower doses with a favorable therapeutic outcome.
Recently, he identified the potential role of urokinase plasminogen activator, a known extracellular protease as a transcription factor and is continuing to decipher its nuclear role. His interests also lies in deciphering the roles of non-coding RNA in chemotherapy resistance.